Fundraising Fox
Delfi Diagnostics
Baltimore, US · Founded 2018 · Delaware corporation · 150 employees on LinkedIn · 14 known investors
Find your way into Delfi Diagnostics
Sign up to see every warm intro you have to Delfi Diagnostics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Delfi Diagnostics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
DELFI Diagnostics develops FirstLook Lung, a blood-based laboratory test for lung cancer screening that identifies genome-wide alterations in individuals eligible for screening. The test offers an alternative to low-dose CT imaging for patients meeting USPSTF criteria and is made available to health systems, primary care providers, and lung screening programs.
Founders & leadership
Delfi Diagnostics was founded in 2018 by Victor Velculescu.
Board
Investors · 14
How we know: the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Foresite Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Illumina Ventures's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Menlo Ventures's portfolio page · a partner's Signal profile · board seat on SEC Form D · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Merck Global Health Innovation Fund's portfolio page · Not right? Tell us
How we know: MSD Global Health Innovation Fund's portfolio page · Not right? Tell us
How we know: OrbiMed's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: OUP (Osage University Partners)'s portfolio page · Not right? Tell us
How we know: Samsara BioCapital's portfolio page · board seat on SEC Form D · Not right? Tell us
How we know: a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$365.9M disclosed across 5 rounds · 2018–2025
▶$34.3MraisedDec 2025 · 50 investors · BiotechnologyRule 506(b)
- Peter B. BachExecutive Officer
- Lee-Ann Smith-FreemanExecutive Officer
- Victor VelculescuDirector
- Susan TousiExecutive Officer, Director
- Amoolya SinghExecutive Officer
- Elizabeth HomansDirector
- Rishi GuptaDirector
- Jacob Van NaardenDirector
- Michael DybbsDirector
- Greg YapDirector
- Justin KaoDirector
- Offering amount
- $60M
- Amount sold
- $34.3M
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$225MraisedJul 2022 · 44 investors · BiotechnologyRule 506(b)
- Peter BachExecutive Officer
- Elizabeth HomansDirector
- Rishi GuptaDirector
- Justin KaoDirector
- Jennifer BuechelExecutive Officer
- Victor VelculescuExecutive Officer, Director, Promoter
- Greg YapDirector
- Douglas SchenkelExecutive Officer
- Michael DybbsDirector
- Jacob Van NaardenDirector
- Nicholas DracopoliExecutive Officer
- Offering amount
- $225M
- Amount sold
- $225M
- First sale
- Jun 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$101.1MraisedJan 2021 · 25 investors · BiotechnologyRule 506(b)
- Victor VelculescuExecutive Officer, Director
- Greg YapDirector
- Nicholas DracopoliExecutive Officer
- William StevensExecutive Officer
- Offering amount
- $101.1M
- Amount sold
- $101.1M
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$5.5MraisedAug 2019 · 7 investors · BiotechnologyRule 506(b)
- Nicholas DracopoliExecutive Officer
- Victor VelculescuExecutive Officer, Director
- Greg YapDirector
- William StevensExecutive Officer
- Offering amount
- $5.5M
- Amount sold
- $5.5M
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$15.3KraisedAug 2019 · 9 investors · BiotechnologyRule 506(b)
- Nicholas DracopoliExecutive Officer
- William J. StevensExecutive Officer
- Victor VelculescuExecutive Officer, Director
- Offering amount
- $15.3K
- Amount sold
- $15.3K
- First sale
- Jun 2018
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Delfi Diagnostics went on to found or lead other companies.
Related companies · 2
Companies working in the same space as Delfi Diagnostics.
Frequently asked questions
- What does Delfi Diagnostics do?
- DELFI Diagnostics develops FirstLook Lung, a blood-based laboratory test for lung cancer screening that identifies genome-wide alterations in individuals eligible for screening. The test offers an alternative to low-dose CT imaging for patients meeting USPSTF criteria and is made available to health systems, primary care providers, and lung screening programs.
- Who founded Delfi Diagnostics?
- Delfi Diagnostics was founded by Victor Velculescu in 2018.
- Who are Delfi Diagnostics's investors?
- Delfi Diagnostics's investors include AV8 Ventures, Foresite Capital, Illumina Ventures, Initiate Venture Partners, Menlo Ventures, Merck Global Health Innovation Fund, MSD Global Health Innovation Fund, Open Field Capital and 6 more.
- How much funding has Delfi Diagnostics raised?
- Delfi Diagnostics has disclosed $365.9M raised across 5 rounds.
- Where is Delfi Diagnostics headquartered?
- Delfi Diagnostics is headquartered in Baltimore, US.